CollabRx and CellNetix Pathology & Laboratories sign agreement CollabRx and CellNetix Pathology & Laboratories announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by CellNetix. Under the terms of the agreement, CollabRx medical and scientific knowledge will be incorporated into the results of genetic sequencing-based tests in oncology provided by CellNetix. CellNetix will leverage CollabRx's knowledgebase in molecular medicine.
CollabRx receives NASDAQ notice of bid price deficiency CollabRx announced today that it received a letter from the NASDAQ stating that the bid price of the company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted on the Nasdaq Capital Market under the symbol CLRX. CollabRx management intends to resolve the situation to allow for continued listing on the Nasdaq Capital Market.